DORC’s ILM-Blue receives China NMPA approval; expanding global reach to prove high-quality and effective solutions to ophthalmic community: Jena, Germany Saturday, March 29, 202 ...
US FDA approves expanded label for ANI Pharma’s Iluvien to treat chronic non-infectious uveitis affecting the posterior segment of the eye: Baudette, Minnesota Monday, March 17, ...
ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center ...
17d
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)ANI plans to begin marketing ILU ...
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) ...
ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has ...
Learn more about whether Glaukos Corporation or PROCEPT BioRobotics Corporation is a better investment based on AAII's A+ ...
Posterior scleritis is a rare but potentially sight-threatening condition that commonly causes diagnostic confusion due to its variable and perplexing clinical symptoms and signs. We present a case of ...
The slit lamp examination is one of the most important diagnostic techniques in ophthalmology. It enables a detailed examination of the anterior, middle and posterior segment of ...
Learn more about whether Glaukos Corporation or iRhythm Technologies, Inc. is a better investment based on AAII's A+ Investor ...
If this is the case, then the ST segment elevation will be in V3 to V6 — and not the septal leads. Because the anatomical opposite of the precordial leads would be posterior leads, which we do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback